# Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

> **NCT00969436** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 450 (actual)

## Conditions studied

- Varicella
- Rubella
- Mumps
- Measles

## Interventions

- **BIOLOGICAL:** GSK Biological's investigational MMRV vaccine 208136
- **BIOLOGICAL:** Priorix™
- **BIOLOGICAL:** Varilrix™

## Key facts

- **NCT ID:** NCT00969436
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-09
- **Primary completion:** 2011-02-21
- **Final completion:** 2011-02-21
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00969436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00969436, "Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00969436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*